Understanding Placebo Responses in Alzheimer's Disease Clinical Trials from the Literature Meta-Data and CAMD Database
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The placebo response and the underlying disease progression is difficult to differentiate in longitudinal Alzheimer's disease (AD) studies, yet it is crucial to understand for designing clinical trials and interpreting results. OBJECTIVES: The placebo response in ADAS-cog11 from various studies was evaluated against model predictions derived from historical placebo data to demonstrate potential interpretation of study results using a prior understanding of expected disease progression. METHODS: The placebo response component from a previously published disease progression model was used to estimate the longitudinal placebo response, and the disease progression in the placebo group in various case studies were evaluated. In addition, placebo data from the Coalition Against Major Diseases (CAMD) database in mild to moderate AD patients is described. RESULTS: The case studies demonstrated potential different results in disease progression in a placebo group, and the impact on understanding the magnitude of drug effect. Baseline cognitive function is an important covariate of disease progression, therefore, it is important to evaluate the baseline severity and predict disease progression accordingly when comparing trial results. Furthermore, study duration, sample size, and study design may affect the placebo response, all of which have the potential to confound understanding of study results. CONCLUSION: The recent failures in Phase III AD studies are not likely due to insufficient cognitive decline in the control groups. A meta-analytic approach using all available data provides a robust understanding of placebo effect, disease progression, and potential interpretation of treatment effects, and offers a useful tool to aid in both trial design and interpretation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior studies in AD suggest that study durations of 18 months are required to observe a decline in placebo groups52”
From Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial (2023) · cites this paper as [52]
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
A Randomized, Controlled Trial of Doxycycline and Rifampin for Patients with Alzheimer's Disease
Loeb, M. B., Molloy, D. W., Smieja, M., Standish, T., Goldsmith, C. H., Mahony, J., Smith, S., Borrie, M., Decoteau, E., Davidson, W., et al. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52109.x · Cited by 241 · cited 2×
“Data used in this analysis were obtained either from the public Study 1 data are obtained from two clinical studies [5, 6] conducted in different time, different sites, and for different drugs, but both studies were 52-week Phase II studies.”
Holford, N. H. G., & Peace, K. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.23.11466 · Cited by 91 · cited 5×
“Thediagnosticcriteriafordementiaand probableADweresameasCaseStudy1above probableADweresameasCaseStudy1above. froma78-week,multi-center,double-blind,4dose cohorts,ascendingdosestudy, Alzheimer’s Disease Trials Drug B) at different times.”
InfluentialRogers, J. A., Polhamus, D. G., Gillespie, W. R., Ito, K., Romero, K., Qiu, R., Stephenson, D. T., Gastonguay, M. R., & Corrigan, B. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9263-3 · Cited by 81 · cited 1×
“Baseline severity is a very important factor when recently, Rogers et al. [17] conducted a meta-analysis combining patient-level and summary-level data and developed disease progression model to describe patients.”
Self-citationSamtani, M. N., Farnum, M., Lobanov, V., Yang, E., Raghavan, N., DiBernardo, A., Narayan, V., & Initiative, A. T. A. D. N. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011405497 · Cited by 80
Romero, K., de Mars, M., Frank, D., Anthony, M., Neville, J., Kirby, L., Smith, K., & Woosley, R. L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.165 · Cited by 55
Self-citationRomero, K., Corrigan, B., Neville, J., Kopko, S., & Cantillon, M. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.51 · Cited by 15
Self-citationMonsch, A. U., Spiegel, R., Berres, M., & Miserez, A. R. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.2255 · Cited by 1
Cited by
Orr, M., Gonzales, M., Garbarino, V., Kautz, T., Palavicini, J., Lopez-Cruzan, M., Dehkordi, S. K., Mathews, J., Zare, H., Xu, P., et al. (2023) · doi:10.21203/rs.3.rs-2809973/v1 · Cited by 319
Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial
Gonzales, M. M., Garbarino, V. R., Kautz, T. F., Palavicini, J. P., Lopez-Cruzan, M., Dehkordi, S. K., Mathews, J. J., Zare, H., Xu, P., Zhang, B., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02543-w · Cited by 334
“Prior studies in AD suggest that study durations of 18 months are required to observe a decline in placebo groups 52 , providing a framework for trial lengths to assess efficacy.”
Beisteiner, R., Matt, E., Fan, C., Baldysiak, H., Schönfeld, M., Philippi Novak, T., Amini, A., Aslan, T., Reinecke, R., Lehrner, J., et al. (2020) · Advanced Science · doi:10.1002/advs.201902583 · Cited by 269
Machine learning for comprehensive forecasting of Alzheimer’s Disease progression
Fisher, C. K., Smith, A. M., Walsh, J. R., Diseases, C. A. M., Simon, A. J., Edgar, C., Jack, C. R., Holtzman, D., Russell, D., Hill, D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49656-2 · Cited by 223
Ströhle, A., Schmidt, D. K., Schultz, F., Fricke, N., Staden, T., Hellweg, R., Priller, J., Rapp, M. A., & Rieckmann, N. (2015) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.07.007 · Cited by 212
“AD Donezepil 18 (0-35) 19 (6-33) 12-54 weeks AD Galantamine 25 (8-49) 16 (9-26) 12-28 weeks AD Ginkgo 9 (2-28) 8 (3-23) 12-26 weeks AD Memantine 17 (3-34) 17 (2-33) 24 weeks-22 months AD Rivastigmine 24 (13-33) 13 (6-16) 12-24 weeks MCI drug 40 (32-43) 27 (17-31) 24 weeks -48 months AD exercise 5 (0-20) 17 (2-25) 6-24…”
Metadata
- Authors
- Ito, K., Corrigan, B., Romero, K., Anziano, R., Neville, J., Stephenson, D., & Lalonde, R.
- Affiliations
- Pfizer (United States) (US)
- Critical Path Institute (US)
- Corresponding author
- Ito, Kaori
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2013-08-20
- Volume
- 37
- Issue
- 1
- Pages
- 173-183
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1720001930
- Cited by
- 62
- References
- 9
- Citations by year
- 2026: 7 · 2025: 1 · 2024: 6 · 2023: 3 · 2022: 5 · 2021: 7 · 2020: 10 · 2019: 7 · 2018: 2 · 2017: 1 · 2016: 4 · 2015: 5 · 2014: 4
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Keywords
- placebo response, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Clinical Trials as Topic, Humans, Placebo Effect, Databases, Factual, Comprehension
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.